Specialty and generic drugmakers
The 3 specialty and generic drugmakers we cover, part of healthcare, largest first. Numbers as of .
- Companies
- 3
- Combined market cap
- $105.5B
- Median PE
- 42.4×
- Median revenue growth
- +2.8%
- Median net margin
- 15.8%
| Company | Market cap | PE | P/S | Revenue growth | Net margin | Dividend yield |
|---|---|---|---|---|---|---|
| TEVATeva Pharmaceutical Industries | $49.7B | 71.1× | 2.9× | +4% | 4.1% | n/m |
| ZTSZoetis | $34.3B | 13.7× | 3.6× | +1% | 27.5% | 2.52% |
| VTRSViatriscaveat | $21.4B | n/m | 1.5× | +4% | −2.8% | n/m |
Other industries in Healthcare
Valuation data, not investment advice. Each company's page has its story, charts, financials and peers.